Skip to content
Clinical Trials – home

Understanding Gadoxetic Acid, Disodium: A Contrast Agent for MRI

1 / 1
trials open to patients / all trials
3+
Countries

In short

The ODYSSEY study is a comprehensive clinical trial investigating the long-term impact of repeated exposure to gadolinium-based contrast agents (GBCAs), specifically Gadoxetic Acid, Disodium, on motor and cognitive functions in neurologically normal adults. This 5-year study aims to assess the safety and potential effects of GBCAs used in contrast-enhanced MRI examinations, comparing GBCA-exposed participants to a non-exposed control group.

At a glance

Study Name
ODYSSEY (Long-term impact of GBCAs on motor and cognitive function following repeated Contrast-Enhanced MRI)
Primary Objective
To assess the potential effect of repeated exposure to GBCAs on motor and cognitive function over 5 years
Study Population
Neurologically normal adults aged 18-65 years
Contrast Agent
Gadoxetic Acid, Disodium (and other GBCAs)
Study Duration
5 years
Key Assessments
Motor function tests, cognitive function tests, blood and urine gadolinium levels, brain MRI scans
Safety Monitoring
Adverse event recording and evaluation

What is Gadoxetic Acid, Disodium?

Gadoxetic acid, disodium is a type of gadolinium-based contrast agent (GBCA) used in medical imaging, specifically in Magnetic Resonance Imaging (MRI) scans. GBCAs are substances that help improve the visibility of internal body structures during an MRI examination. Gadoxetic acid is also known by other names, including its brand names, which may vary depending on the manufacturer.

Medical Uses

Gadoxetic acid, disodium is primarily used to enhance the quality of MRI scans for various medical conditions. Some of the key uses include:

  • Liver imaging: It's particularly useful for patients with chronic liver diseases, such as cirrhosis, to detect and monitor hepatocellular carcinoma (HCC), a type of liver cancer.
  • Cancer detection and monitoring: It's used in screening for breast cancer, especially in patients with dense breast tissue.
  • Prostate cancer diagnosis: For patients with elevated prostate-specific antigen (PSA) levels who are under surveillance for prostate cancer.
  • Colorectal cancer surveillance: To monitor for liver metastases in patients with low-grade colorectal cancer.
  • Pancreatic imaging: For surveillance of certain pancreatic conditions, such as intraductal papillary mucinous neoplasm (IPMN).

How is it Administered?

Gadoxetic acid, disodium is administered as an intravenous injection. The typical dose is 0.1 milliliters per kilogram of body weight. It's usually given just before or during the MRI scan, depending on the specific imaging protocol being used.

Safety Concerns and Long-Term Effects

While gadoxetic acid and other GBCAs are generally considered safe, there are some concerns about their long-term effects, particularly with repeated use. Some key points to consider:

  • Gadolinium retention: There's evidence that small amounts of gadolinium can be retained in the body, including in the brain, after multiple GBCA administrations.
  • Renal function: Patients with impaired kidney function (with an estimated glomerular filtration rate less than 60 mL/min/1.73 m²) may be at higher risk for complications and are typically excluded from receiving GBCAs.
  • Pregnancy and breastfeeding: GBCAs are generally avoided in pregnant or nursing women due to potential risks to the fetus or infant.

Ongoing Research: The ODYSSEY Study

To better understand the long-term effects of repeated GBCA use, including gadoxetic acid, a large-scale study called ODYSSEY is currently underway. This study aims to:

  • Evaluate the potential effects of repeated GBCA administrations on motor and cognitive functions in neurologically normal adults.
  • Compare GBCA-exposed individuals to a control group not exposed to GBCAs over a 5-year period.
  • Assess changes in motor and cognitive function through various tests and examinations.
  • Monitor gadolinium concentrations in blood and urine samples of participants.

Patient Considerations

If you're scheduled to receive gadoxetic acid or any other GBCA for an MRI, here are some important points to discuss with your healthcare provider:

  • Inform your doctor about any allergies, especially to contrast agents or metals.
  • Discuss your complete medical history, including any kidney problems or previous reactions to contrast agents.
  • If you're pregnant or breastfeeding, make sure to inform your healthcare team.
  • Ask about the necessity of the contrast agent for your specific examination and if there are any alternatives.
  • If you're participating in the ODYSSEY study or any similar research, ensure you understand the commitments and potential risks involved.

Remember, while there are some concerns about the long-term effects of GBCAs, they remain an important tool in medical imaging, often providing crucial information for diagnosis and treatment planning. The benefits of using these agents typically outweigh the potential risks for most patients, but it's always important to have an open discussion with your healthcare provider about your specific situation.

Questions people often ask

Conditions where Gadoxetic Acid, Disodium is being studied

Each condition opens its own overview and trial list

Trials with Gadoxetic Acid, Disodium

Recruiting trials first

See all 1 →
Quick filters
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).